Related references
Note: Only part of the references are listed.Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application
Ran Wei et al.
CANCER LETTERS (2020)
A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas
Martin F. Orth et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS).
Christina Lynn Roland et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma
Takuya Kakimoto et al.
ONCOLOGY LETTERS (2019)
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
Ghaneya Al-Khadairi et al.
CANCERS (2019)
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
Indu Ramachandran et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1c259 T Cells in Synovial Sarcoma
Sandra P. D'Angelo et al.
CANCER DISCOVERY (2018)
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
Remy Thomas et al.
FRONTIERS IN IMMUNOLOGY (2018)
Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma The EORTC 62961-ESHO 95 Randomized Clinical Trial
Rolf D. Issels et al.
JAMA ONCOLOGY (2018)
Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1
Kunio Iura et al.
HUMAN PATHOLOGY (2017)
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
Alessandro Gronchi et al.
LANCET ONCOLOGY (2017)
MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1
Kunio Iura et al.
VIRCHOWS ARCHIV (2017)
Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas
Alexander J. Lazar et al.
CELL (2017)
Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes
Jason Roszik et al.
CLINICAL SARCOMA RESEARCH (2017)
Dissecting the role of tumor-infiltrating lymphocytes (TIL) in patients with high-risk soft-tissue sarcoma (STS) receiving neo-adjuvant chemotherapy (NAC) with regional hyperthermia (RHT)
R. Issels et al.
ANNALS OF ONCOLOGY (2016)
The urgent need to recover MHC class I in cancers for effective immunotherapy
Federico Garrido et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma
Elizabeth Shurell et al.
ONCOTARGET (2016)
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles et al.
NATURE MEDICINE (2015)
Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma
Lotte Spel et al.
ONCOTARGET (2015)
Increased NY-ESO-1 Expression and Reduced Infiltrating CD3+T Cells in Cutaneous Melanoma
Mara Giavina-Bianchi et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2015)
NY-ESO-1 (CTAG1B) expression in mesenchymal tumors
Makoto Endo et al.
MODERN PATHOLOGY (2015)
Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma
Jessica A. Hemminger et al.
MODERN PATHOLOGY (2014)
The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas
Jessica A. Hemminger et al.
MODERN PATHOLOGY (2013)
NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms
Jessica A. Hemminger et al.
MODERN PATHOLOGY (2013)
NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma
Seth M. Pollack et al.
CANCER (2012)
NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis
Jin-Ping Lai et al.
MODERN PATHOLOGY (2012)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Immune parameters affecting the efficacy of chemotherapeutic regimens
Laurence Zitvogel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
γ-Radiation Promotes Immunological Recognition of Cancer Cells through Increased Expression of Cancer-Testis Antigens In Vitro and In Vivo
Anu Sharma et al.
PLOS ONE (2011)
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study
Rolf D. Issels et al.
LANCET ONCOLOGY (2010)
Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer
A Mischo et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer
AO Gure et al.
CLINICAL CANCER RESEARCH (2005)
Cancer/testis antigens, gametogenesis and cancer
AJG Simpson et al.
NATURE REVIEWS CANCER (2005)
Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer
T Knösel et al.
NEOPLASIA (2005)
Tissue microarray evaluation of melanoma antigen E (MAGE) tumor-associated antigen expression - Potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma
M Bolli et al.
ANNALS OF SURGERY (2002)
MAGE antigen expression in monophasic and biphasic synovial sarcoma
CR Antonescu et al.
HUMAN PATHOLOGY (2002)
Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7
AA Jungbluth et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Share Paper
